Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **multi-ingredient pharmaceutical kit/combination** comprising dexamethasone sodium phosphate, bupivacaine, povidone-iodine, and isopropyl alcohol, apparently intended to support local analgesia/anesthesia procedures such as injection or nerve-block workflows. Mechanistically, dexamethasone sodium phosphate is a synthetic corticosteroid that acts primarily through the glucocorticoid receptor to reduce inflammatory signaling and tissue irritation, while bupivacaine is a long-acting amide local anesthetic that blocks voltage-gated sodium channels and thereby inhibits peripheral nerve conduction. Povidone-iodine and isopropyl alcohol function as topical antiseptic/disinfectant components used to reduce microbial burden at the procedural site rather than as direct analgesic agents. Based on the provided context, this exact combination most likely corresponds to an unapproved kit-type product related to MARDEX 25 KIT and associated with Asclemed USA for analgesia/anesthesia use; however, public-source verification for the exact four-component name is limited.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone sodium phosphate + isopropyl alcohol + povidone-iodine + bupivacaine.